Seer Price to Free Cash Flow Ratio 2020-2022 | SEER
Historical price to free cash flow ratio values for Seer (SEER) since 2020.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Seer Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2022-07-01 | 9.81 | 0.00 | |
| 2022-03-31 | 15.24 | $-0.94 | 0.00 |
| 2021-12-31 | 22.81 | $-0.88 | 0.00 |
| 2021-09-30 | 34.53 | $-1.71 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.613B | $0.007B |
| Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $163.597B | 9.95 |
| Bio-Rad Laboratories (BIO.B) | United States | $14.907B | 32.33 |
| QIAGEN (QGEN) | Netherlands | $10.865B | 17.15 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.248B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.228B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.901B | 48.18 |
| Emergent Biosolutions (EBS) | United States | $1.599B | 6.85 |
| Myovant Sciences (MYOV) | United Kingdom | $1.236B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.320B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.114B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.104B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.103B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.087B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
